Third Opinion Trial Synopsis
Doctors are testing a new treatment for a type of cancer called multiple myeloma. This treatment uses four drugs called isatuximab, carfilzomib, pomalidomide, and dexamethasone. Isatuximab tries to stop cancer cells from growing and spreading. Carfilzomib stops cancer cells from growing by blocking certain proteins. Pomalidomide slows or shrinks the cancer. Dexamethasone is a medicine that lowers the body's immune response, and can help treat some types of cancer. Using all four drugs together could help kill more cancer cells. This trial is for people with multiple myeloma that has come back or has not responded to other treatments.

Trial Summary
This phase II trial studies the effect of isatuximab, carfilzomib, pomalidomide, and dexamethasone in treating patients with multiple myeloma that has come back (relapsed) or does not respond to treatment (refractory). Isatuximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Carfilzomib may stop the growth of cancer cells by blocking some of the proteins needed for cell growth. Pomalidomide may help shrink or slow the growth of mutliple myeloma. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Giving isatuximab, carfilzomib, pomalidomide, and dexamethasone may kill more cancer cells.